

Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis

NCT01420562

Status RECRUITING
Sponsor Universitaire Ziekenhuizen KU Leuven
Enrollment 55 participants

Key Eligibility Criteria

Inclusion (1)

- Patients receiving allogeneic stem cell transplantation - Treated with prophylactic posaconazole: oral suspension (200mg three times daily) or tablet (300mg once daily) to prevent invasive fungal infections

Exclusion (4)

- Gastroparesis
- Vomiting or diarrhea within 2 hours after intake of posaconazole
- Concomitant administration of potent inducers of the enzyme UGT1A4: carbamazepine, phenytoin, phenobarbital, rifabutin, rifampicin,...
- Age under 18 years

Locations (1 total)

University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium